CELLPRO BEGINS PHASE III TRIAL IN MULTIPLE MYELOMA; New Trial Designed to Demonstrate Tumor-Cell Depletion.
Business Wire › January 16, 1995
Linked as:
Extract
CELLPRO BEGINS PHASE III TRIAL IN MULTIPLE MYELOMA; New Trial Designed to Demonstrate Tumor-Cell Depletion.
SEATTLE--(BUSINESS WIRE)--Jan. 16, 1995--CellPro Inc. (NASDAQ:CPRO) announced today that it had begun a Phase III clinical trial to demonstrate that using its CEPRATE SC Stem Cell Concentration System to positively select CD34 antigen-expressing cells from the p...
See the full content of this document
Sponsored links
